GH Research PLC (NASDAQ:GHRS - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the twelve brokerages that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $44.00.
Several equities research analysts have issued reports on GHRS shares. Wells Fargo & Company started coverage on shares of GH Research in a report on Monday, July 27th. They issued an "overweight" rating and a $44.00 price target on the stock. New Street Research set a $65.00 price objective on shares of GH Research in a report on Monday, August 10th. HC Wainwright decreased their target price on shares of GH Research from $65.00 to $55.00 and set a "buy" rating on the stock in a research report on Tuesday, November 17th. Zacks Research raised shares of GH Research from a "strong sell" rating to a "hold" rating in a research note on Thursday, August 13th. Finally, Cantor Fitzgerald upped their target price on shares of GH Research from $35.00 to $40.00 and gave the company an "overweight" rating in a research note on Friday, August 7th.
Get Our Latest Stock Analysis on GH Research
GH Research News Roundup
These are some of the GHRS news items that stood out recently:
- Positive Sentiment: Guggenheim analyst commentary also indicates an expectation that GHRS shares could rise. Read article
- Positive Sentiment: HC Wainwright maintained its Buy rating and $55 target, while raising several quarterly and annual EPS estimates, including for 2026–2030. These revisions generally point to smaller expected losses, though the firm lowered its Q4 2027 estimate slightly. Read analyst estimate report
- Negative Sentiment: A separate report attributed a sharp share decline to an analyst downgrade, a potential near-term headwind that contrasts with the bullish targets from other analysts. The entry does not specify the downgrading analyst or rationale. Read article
GH Research Trading Down 5.5%
GHRS opened at $17.53 on Friday. The stock's 50 day simple moving average is $21.37 and its 200-day simple moving average is $21.70. The stock has a market cap of $1.20 billion, a PE ratio of -18.45 and a beta of 1.31. GH Research has a 1 year low of $12.04 and a 1 year high of $31.44.
GH Research (NASDAQ:GHRS - Get Free Report) last issued its earnings results on Friday, November 13th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.13. Equities analysts forecast that GH Research will post -1.08 earnings per share for the current fiscal year.
Institutional Investors Weigh In On GH Research
Institutional investors have recently added to or reduced their stakes in the stock. Troluce Capital Advisors LLC increased its stake in shares of GH Research by 165.4% in the first quarter. Troluce Capital Advisors LLC now owns 990,472 shares of the company's stock valued at $13,926,000 after buying an additional 617,260 shares in the last quarter. Braidwell LP acquired a new position in GH Research during the 2nd quarter worth about $5,571,000. Marshall Wace LLP lifted its position in GH Research by 46.3% during the 3rd quarter. Marshall Wace LLP now owns 68,298 shares of the company's stock worth $1,604,000 after buying an additional 21,601 shares in the last quarter. Renaissance Technologies LLC acquired a new position in GH Research during the 1st quarter worth about $290,000. Finally, Militia Capital Management LLC acquired a new position in GH Research during the 3rd quarter worth about $470,000. 56.90% of the stock is owned by institutional investors and hedge funds.
About GH Research
(
Get Free Report)
GH Research plc is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders. The company is based in Dublin, Ireland, and its research centers on mebufotenin, also known as 5-MeO-DMT. Its lead investigational candidate, GH001, is an inhaled formulation being studied for treatment-resistant depression. GH Research is also developing other mebufotenin-based candidates and delivery approaches. These treatments remain investigational and are not approved for general use.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider GH Research, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GH Research wasn't on the list.
While GH Research currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.